ArticleThe pharmacogenomics journal2016
Pharmacogenomic variants have larger effect sizes than genetic variants associated with other dichotomous complex traits.
Article in The pharmacogenomics journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Analysis of genetic and clinical factors associated with buprenorphine response.Drug and alcohol dependence · 2021Pooled it
- Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation.The pharmacogenomics journal · 2020Pooled it
- New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation.The pharmacogenomics journal · 2018Pooled it
- Genome Wide Association Study Identifies theJournal of the American Heart Association · 2018Pooled it
- Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide.Hypertension (Dallas, Tex. : 1979) · 2017Pooled it
- Pharmacogenomics polygenic risk score for drug response prediction using PRS-PGx methods.Nature communications · 2022Trial
- Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Trial
- Genomic Association Analysis Reveals Variants Associated With Blood Pressure Response to Beta-Blockers in European Americans.Clinical and translational science · 2019Trial
- Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes.The pharmacogenomics journal · 2018Trial
- Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials.Journal of the American Heart Association · 2017Trial
- Lymphocyte count polygenicity underlies dimethyl fumarate-associated lymphopenia in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Genetic Determinants of Infectious Diseases in the Qatari Population.Epidemiologia (Basel, Switzerland) · 2026Article
- Pharmacogenomics of risperidone in autism spectrum disorder: a minireview.Frontiers in pharmacology · 2026Review
- Genome-Wide Association Study of Varenicline-Aided Smoking Cessation.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025Article
- Genetic Variation in Hydrochlorothiazide Response-Related Genes Among Hypertensive Individuals in Soweto, South Africa.Clinical and translational science · 2025Article
- Treatment-resistant depression: role of genetic factors in the perspective of clinical stratification and treatment personalisation.Molecular psychiatry · 2025Review
- Near, far, wherever you are: phenotype-related variation in pharmacogenomic effect sizes across the psychiatric drug literature.Frontiers in pharmacology · 2025Article
- Genome-wide association reveals a locus in neuregulin 3 associated with gabapentin efficacy in women with chronic pelvic pain.iScience · 2024Article
- Contradiction in Star-Allele Nomenclature of Pharmacogenes between Common Haplotypes and Rare Variants.Genes · 2024Article
- Pharmacogenomics: current status and future perspectives.Nature reviews. Genetics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
It has been suggested that pharmacogenomic phenotypes are influenced by genetic variants with larger effect sizes than other phenotypes, such as complex disease risk. This is presumed to reflect the fact that relevant environmental factors (drug exposure) are appropriately measured and taken into account. To test this hypothesis, we performed a systematic comparison of effect sizes between pharmacogenomic and non-pharmacogenomic phenotypes across all genome-wide association studies (GWAS) reported in the NHGRI GWAS catalog. We found significantly larger effect sizes for studies focused on pharmacogenomic phenotypes, as compared with complex disease risk, morphological phenotypes and endophenotypes. We found no significant differences in effect sizes between pharmacogenomic studies focused on adverse events versus those focused on drug efficacy. Furthermore, we found that this pattern persists among sample size-matched studies, suggesting that this pattern does not reflect overestimation of effect sizes due to smaller sample sizes in pharmacogenomic studies.The Pharmacogenomics Journal advance online publication, 7 July 2015; doi:10.1038/tpj.2015.47.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.